# Safety and Efficacy Study of GCS-100LE in the Treatment of Multiple Myeloma

> **NCT00609817** · PHASE1 · TERMINATED · sponsor: **La Jolla Pharmaceutical Company** · enrollment: 9 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** GCS-100
- **DRUG:** Bortezomib/Dexamethasone

## Key facts

- **NCT ID:** NCT00609817
- **Lead sponsor:** La Jolla Pharmaceutical Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-05
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Lack of funding
- **Last updated:** 2013-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00609817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00609817, "Safety and Efficacy Study of GCS-100LE in the Treatment of Multiple Myeloma". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT00609817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*